Herpes zoster vaccine (Zostavax®): Cellulitic injection site reaction or bacterial cellulitis?
نویسنده
چکیده
A 70 y old woman presented with a cellulitic reaction following Zostavax® injection. This reaction could be differentiated from bacterial cellulitis on the basis of the temporal relationship between vaccination and onset of the reaction, its non progression and unresponsiveness to antibiotic therapy. Alerting health care providers to this type of reaction, also seen with pneumococcal and pertussis containing vaccines, should avoid the inappropriate use of antibiotics.
منابع مشابه
A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax.
The vaccine Zostavax has been shown to prevent herpes zoster (HZ) and postherpetic neuralgia and is recommended for individuals > or =60 years of age. This study compared the safety and the immunogenicity of a refrigerator-stable formulation (Zostavax refrigerated) with those of the current formulation (Zostavax frozen) in subjects > or =50 years of age. Subjects with a negative history for HZ ...
متن کاملImmunogenicity and Safety of a Live Attenuated Zoster Vaccine (ZOSTAVAX™) in Korean Adults
A live attenuated zoster vaccine (ZOSTAVAX™, Merck & Co., Inc.) was approved by the Korea Ministry of Food and Drug Safety in 2009. However, the immunogenicity and safety of the vaccine has not been assessed in Korean population. This is multi-center, open-label, single-arm study performed with 180 healthy Korean adults ≥ 50 yr of age. The geometric mean titer (GMT) and geometric mean fold rise...
متن کاملUpdate on Recommendations for Use of Herpes Zoster Vaccine
Herpes zoster vaccine (Zostavax [Merck & Co., Inc.]) was licensed in 2006 and recommended by the Advisory Committee on Immunization Practices (ACIP) in 2008 for prevention of herpes zoster (shingles) and its complications among adults aged ≥60 years. The Food and Drug Administration (FDA) approved the use of Zostavax in 2011 for adults aged 50 through 59 years based on a large study of safety a...
متن کاملUnsettled issues of Zostavax vaccine.
TO THE EDITOR—The article by Schmader et al [1] summarizing a Zostavax trial in 50to 59-year-old participants raises new concerns and rekindles others [2]. Zostavax vaccine introduces a new virus which, like chickenpox, becomes latent in cranial nerves and autonomic and dorsal root ganglia [3]. These 2 versions of the same virus will permanently populate similar anatomic sites. Moreover, clinic...
متن کاملExacerbation of zoster interstitial keratitis after zoster vaccination in an adult.
T wo different forms of varicella-zoster virus (VZV) immunizations are available. Children are vaccinated with Varivax to reduce the risk of primary infection with VZV, and Zostavax is given to reduce the risk of VZV reactivation in adults. In a large prospective trial of adults older than 60 years, vaccination with Zostavax was shown to decrease the incidence of herpes zoster by 51.3% as well ...
متن کامل